Report Id: SNS/HC/1187 | May 2022 | Region: Global | 125 Pages
Report Scope & Overview:
The Cell & Gene Therapy Manufacturing Services Market Size was valued at USD 16.92 billion in 2022 and is expected to reach USD 30.86 billion by 2030, and grow at a CAGR of 7.8% over the forecast period 2023-2030.
Growing agreements and partnerships between CDMOs and pharmaceutical companies are propelling the cell and gene therapy manufacturing services market. The increasing rate of investment in new technologies and pharmaceutical research and development activities are also contributing to the expansion of the cell & gene therapy manufacturing services sector. Furthermore, as cancer and other diseases become more prevalent, the cell and gene therapy manufacturing services market is expanding.
Excessive operational expenses may limit the expansion of the cell and gene therapy manufacturing services business. It could raise the overall cost of the service and, to some extent, limit the potential in the cell and gene therapy manufacturing services market.
Cancer and Chronic Diseases are becoming more common.
Increase in number of investments.
The quantity of clinical preliminaries is expanding.
Regulatory Environment That Is Favorable
Operational charges are high.
Approvals for drugs and a healthy pipeline
Rise in number cell therapy.
There is a scarcity of reliable vectors for cell and gene therapy.
Scarcity of therapy-specific tests
IMPACT OF COVID-19
The current COVID-19 pandemic has had a favorable impact on the manufacture of cell and gene therapies. Several companies increased their vector production capacities and formed strategic partnerships to develop experimental medicines. This is in response to the urgent need for effective treatments as well as an anti-infection vaccination. Tevogen Bio, for example, teamed up with Biocentric to develop Tevogen’s COVID-19 T-Cell Therapy in March 2021.
The ratio of successful treatment to the number of clinical trials of cellular and gene-modified therapeutic products has improved in recent years in the healthcare industry. This is due to greater science and medical awareness of the safety risks associated with their use. In early 2020, there were 362 phase III clinical studies, with the number likely to rise dramatically in the future years.
By Therapy Type:
The high number of active clinical trials and the increasing number of goods entering the market are both contributing to the rise. To understand the potential of cell therapies for the treatment of various cancer indications, more than 250 clinical studies concentrating on CAR T cell treatments and other cell therapies are being examined. Furthermore, biopharma companies are seeing allogeneic CAR T cell therapy as a more attractive business strategy than current manufacturing and economic models.
By Scale Type:
This is due to a robust and rapidly expanding pipeline of cell and gene therapies around the world. More than 900 clinical trials for various cell treatments are currently conducted as of March 2020. According to the Journal of Gene Medicine, the number of gene therapy clinical studies has increased to 3,036 in 2020. This high figure reflects the rising need for manufacturing services in the development of preclinical product candidates.
By Mode Type:
The main contribution to this area is the presence of a large number of large capital businesses, as well as academic institutes with individualized patient treatment programs. Improved process troubleshooting agility, ownership of supply networks, and efficient creation of a corporate knowledge base to aid future in-house scale-up are all major elements driving the segment growth.
By Workflow type:
The development of very well and robust technologies for cell therapy production has become increasingly critical as more medicines progress from clinical trials to regulatory approval. Process development solutions improve the quality and safety profiles of candidate programs while increasing efficiency.
There are some of major key players: Merck KGaA, Thermo Fisher Scientific, Catalent Inc., Lonza, Takara Bio Inc., Wuxi Advanced Therapies, F. Hoffmann-La Roche Ltd, Samsung Biologics, Bluebird Bio Inc., Novartis AG, Boehringer Ingelheim, Hitachi Chemical Co., Ltd., Miltenyi Biotec, Cellular Therapeutics.
KEY MARKET SEGMENTS:
By Therapy Type
Gene Therapy Manufacturing
Cell Therapy Manufacturing
Non-Stem Cell Therapy
Stem Cell Therapy
By Scale Type
Commercial Scale Manufacturing
Pre-commercial/ R&D Scale Manufacturing
By Mode type
By Workflow type
Fill & Finish Operations
Analytical And Quality Testing
Raw Material Testing
North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa make up the cell and gene therapy production services market. North America, Europe, and Asia Pacific accounted for the highest proportion of the cell and gene therapy manufacturing services market in 2020. The rising commonness of disease and developing exploration exertion in malignant growth and undifferentiated cells are liable for a significant portion of the North American market.
Rest of Europe
Rest of Asia-Pacific
The Middle East & Africa
Rest of Middle East & Africa
Rest of Latin America
|Market Size in 2022||US$ 16.92 Billion|
|Market Size by 2030||US$ 30.86 Billion|
|CAGR||CAGR of 7.8% From 2023 to 2030|
|Report Scope & Coverage||Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook|
|Key Segments||• By Type (Gene Therapy Manufacturing, Cell Therapy Manufacturing)
• By Scale Type (Commercial Scale Manufacturing, Pre-commercial/ R&D Scale Manufacturing)
• By Mode type (In-house Manufacturing, Contract Manufacturing)
• By Workflow type (Cell Processing, Fill & Finish Operations, Vector Production, Analytical And Quality Testing, Cell Banking, Process Development, Raw Material Testing, Others)
|Regional Analysis/Coverage||North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
|Company Profiles||Merck KGaA, Thermo Fisher Scientific, Catalent Inc., Lonza, Takara Bio Inc., Wuxi Advanced Therapies, F. Hoffmann-La Roche Ltd, Samsung Biologics, Bluebird Bio Inc., Novartis AG, Boehringer Ingelheim, Hitachi Chemical Co., Ltd., Miltenyi Biotec, Cellular Therapeutics.|
|DRIVERS||• Cancer and Chronic Diseases are becoming more common.
• Increase in number of investments.
• The quantity of clinical preliminaries is expanding.
|RESTRAINTS||• Operational charges are high.|
Frequently Asked Questions (FAQ) :
Cell & Gene Therapy Manufacturing Services Market is expected to reach USD 56.7 billion by 2028.
North America, Europe, and the Asia Pacific accounted for the highest proportion of the cell and gene therapy manufacturing services market.
The market is divided into four segments and the segments are By Therapy Type, By Scale Type, By Mode type, and By Workflow type.
The challenges faced by Cell & Gene Therapy Manufacturing Services Market is there is a scarcity of reliable vectors for cell and gene therapy, and the Scarcity of therapy-specific tests.
key drivers of the Cell & Gene Therapy Manufacturing Services Market are an Increase in a number of investments, and the quantity of clinical preliminaries is expanding.
Table of Contents
1.1 Market Definition
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
4. Impact Analysis
4.1 COVID-19 Impact Analysis
4.2 Impact of Ukraine- Russia war
4.3 Impact of ongoing Recession
4.3.2 Impact on major economies
126.96.36.199 United Kingdom
188.8.131.52 South Korea
184.108.40.206 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces Model
7. PEST Analysis
8. Cell & Gene Therapy Manufacturing Services Market Segmentation, by Type
8.1 Gene Therapy Manufacturing
8.2 Cell Therapy Manufacturing
8.2.1 Non-Stem Cell Therapy
8.2.2 Stem Cell Therapy
9. Cell & Gene Therapy Manufacturing Services Market Segmentation, by Scale Type
9.1 Commercial Scale Manufacturing
9.2 Pre-commercial/ R&D Scale Manufacturing
10. Cell & Gene Therapy Manufacturing Services Market Segmentation, By Mode type
10.1 In-house Manufacturing
10.2 Contract Manufacturing
11. Cell & Gene Therapy Manufacturing Services Market Segmentation, By Workflow type
11.1 Cell Processing
11.2 Fill & Finish Operations
11.3 Vector Production
11.4 Analytical and Quality Testing
11.5 Cell Banking
11.6 Process Development
11.7 Raw Material Testing
12. Regional Analysis
12.2 North America
12.3.6 The Netherlands
12.3.7 Rest of Europe
12.4.2 South Korea
12.4.6 Rest of Asia-Pacific
12.5 The Middle East & Africa
12.5.3 South Africa
12.6 Latin America
12.6.3 Rest of Latin America
13. Company Profiles
13.1 Merck KGaA
13.1.2 Products/ Services Offered
13.1.3 SWOT Analysis
13.1.4 The SNS view
13.2 Thermo Fisher Scientific
13.3 Catalent Inc.
13.5 Takara Bio Inc.
13.6 Wuxi Advanced Therapies
13.7 F. Hoffmann-La Roche Ltd
13.8 Samsung Biologics
13.9 Bluebird Bio Inc.
13.10 Novartis AG
13.11 Boehringer Ingelheim
13.12 Hitachi Chemical Co., Ltd.
13.12 Miltenyi Biotec
13.13 Cellular Therapeutics
14. Competitive Landscape
14.1 Competitive Benchmarking
14.2 Market Share Analysis
14.3 Recent Developments
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of a good and accurate research report and selecting the best methodology to complete the research is the toughest part. Since the research reports, we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach a stage wherein we can provide our clients best and most accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brainstorming sessions to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research as the name suggests is a research process wherein, we collect data through readily available information. In this process, we use various paid and unpaid databases to which our team has access and gather data through the same. This includes examining listed companies’ annual reports, Journals, SEC filling, etc. Apart from this, our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various universities as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content-specific facts that can be sued to solve specific problems. Since the collected data is fresh and first-hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply sides of the industry to make sure we land an accurate judgment and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses, and observation of on-field participants. The below-mentioned chart should give a better understanding of part 1 of the primary interview.
Part 2: In this part of the primary research the data collected via secondary research and part 1 of the primary research is validated with the interviews with individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence center, our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real-time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but is not limited to getting rid of the many typos, duplication of numbers, or missing any important information. The people involved in this process include technical content writers, research heads, and graphics people. Once this process is completed the title gets uploaded on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.